Clinical Trial Update: Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating a sympathicomimetic agonist in patients with myeloproliferative neoplasms carrying JAK2 mutations, including primary my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Myeloproliferative Neoplasm
• Polycythemia Vera

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Myeloproliferative Neoplasm, Primary Myelofibrosis | Phase 2 | Status: COMPLETED